Cargando…

Interleukin-32α promotes the proliferation of multiple myeloma cells by inducing production of IL-6 in bone marrow stromal cells

Multiple myeloma (MM) is a malignant plasma disease closely associated with inflammation. In MM bone marrow microenvironment, bone marrow stromal cells (BMSCs) are the primary source of interleukin-6 (IL-6) secretion, which promotes the proliferation and progression of MM cells. However, it is still...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Xuanru, Yang, Li, Wang, Gang, Zi, Fuming, Yan, Haimeng, Guo, Xing, Chen, Jing, Chen, Qingxiao, Huang, Xi, Li, Yi, Zhang, Enfan, Wu, Wenjun, Yang, Yang, He, Donghua, He, Jingsong, Cai, Zhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696226/ https://www.ncbi.nlm.nih.gov/pubmed/29190960 http://dx.doi.org/10.18632/oncotarget.21611

Ejemplares similares

Quercetin induces cell apoptosis of myeloma and displays a synergistic effect with dexamethasone in vitro and in vivo xenograft models
por: He, Donghua, et al.
Publicado: (2016)

BAFF is involved in macrophage-induced bortezomib resistance in myeloma
por: Chen, Jing, et al.
Publicado: (2017)

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway
por: Yang, Li, et al.
Publicado: (2018)

Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease
por: He, Jingsong, et al.
Publicado: (2018)

Myeloma-derived IL-32γ induced PD-L1 expression in macrophages facilitates immune escape via the PFKFB3-JAK1 axis
por: Liu, Yang, et al.
Publicado: (2022)

The adverse impact of a gain in chromosome 1q on the prognosis of multiple myeloma treated with bortezomib-based regimens: A retrospective single-center study in China
por: Chen, Qingxiao, et al.
Publicado: (2022)

CCL2 promotes macrophages-associated chemoresistance via MCPIP1 dual catalytic activities in multiple myeloma
por: Xu, Ruyi, et al.
Publicado: (2019)

The NEDD4‐1 E3 ubiquitin ligase: A potential molecular target for bortezomib sensitivity in multiple myeloma
por: Huang, Xi, et al.
Publicado: (2019)

High serum IL-17A is associated with bone destruction in newly diagnosed multiple myeloma patients
por: Dong, Mengmeng, et al.
Publicado: (2022)

HMGB1 knockdown increases MM cell vulnerability by regulating autophagy and DNA damage repair
por: Guo, Xing, et al.
Publicado: (2018)

Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression
por: Cao, Liqin, et al.
Publicado: (2022)

TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy
por: Chen, Jing, et al.
Publicado: (2023)

Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma
por: He, JingSong, et al.
Publicado: (2021)

Dihydroartemisinin Modulates Apoptosis and Autophagy in Multiple Myeloma through the P38/MAPK and Wnt/β-Catenin Signaling Pathways
por: Wu, Xiuhua, et al.
Publicado: (2020)

Fibroblast activation protein α in tumor microenvironment: Recent progression and implications (Review)
por: ZI, FUMING, et al.
Publicado: (2015)

Expression of interleukin-32 in bone marrow of patients with myeloma and its prognostic significance
por: Wang, Gang, et al.
Publicado: (2019)

RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-κB and MAPK signaling pathways
por: Qu, Jianwei, et al.
Publicado: (2021)

The many substrates and functions of NEDD4-1
por: Huang, Xi, et al.
Publicado: (2019)

Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
por: Han, Xiaoyan, et al.
Publicado: (2021)

Corrigendum: Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
por: Han, Xiaoyan, et al.
Publicado: (2021)

RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential
por: Qu, Jianwei, et al.
Publicado: (2022)

Identification of key candidate genes and pathways in multiple myeloma by integrated bioinformatics analysis
por: Yan, Haimeng, et al.
Publicado: (2019)

Analysis of High-Risk Extramedullary Relapse Factors in Newly Diagnosed MM Patients
por: Yue, Xiaoyan, et al.
Publicado: (2022)

Efficacy of Intermittent, Oral Famciclovir Prophylaxis for Bortezomib-Induced Herpes Zoster in Multiple Myeloma Patients
por: Zheng, Gaofeng, et al.
Publicado: (2022)

NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma
por: Huang, Xi, et al.
Publicado: (2022)

Metabolic reprogramming in macrophage responses
por: Liu, Yang, et al.
Publicado: (2021)

Differentiation Syndrome with Severe Abdominal Pain During Induction Treatment of Acute Promyelocytic Leukemia: A Case Report
por: Yan, Haimeng, et al.
Publicado: (2021)

Liquid biopsy by analysis of circulating myeloma cells and cell-free nucleic acids: a novel noninvasive approach of disease evaluation in multiple myeloma
por: Li, Shuchan, et al.
Publicado: (2023)

The effect of marrow stromal cells on TRAF6 expression levels in myeloma cells
por: Huang, Hongming, et al.
Publicado: (2017)

Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma
por: Ria, Roberto, et al.
Publicado: (2020)

Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression
por: Maiso, Patricia, et al.
Publicado: (2021)

Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
por: He, Jingsong, et al.
Publicado: (2020)

Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma
por: Wei, GuoQing, et al.
Publicado: (2017)

Bone Marrow Stromal Cells Derived MCP-1 Reverses the Inhibitory Effects of Multiple Myeloma Cells on Osteoclastogenesis by Upregulating the RANK Expression
por: Liu, Zhiqiang, et al.
Publicado: (2013)

Evidences of Early Senescence in Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells
por: André, Thibaud, et al.
Publicado: (2013)

Integrated bioinformatic analysis of HNF1A in human cancers
por: Zhang, Enfan, et al.
Publicado: (2021)

Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells
por: Zdzisińska, Barbara, et al.
Publicado: (2008)

Interleukin-32: Frenemy in cancer?
por: Han, Sora, et al.
Publicado: (2019)

TRAF6 Silencing Attenuates Multiple Myeloma Cell Adhesion to Bone Marrow Stromal Cells
por: Morgan, Jonathan J., et al.
Publicado: (2019)

Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease
por: Garcia-Gomez, Antonio, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3f5rbi5pl1vr0ur8rhnje0e47j